Private Equity
7 min read · 30 November 2017
Real Ventures has raised $180 million for its fourth early-stage fund with the help of an expanded LP base, including two powerhouse Asian investors won over by the firm’s artificial-intelligence strategy. The Montréal venture firm this week announced the close of Real Ventures IV at its hard cap. It is backed by more than 60 LPs, among them new LPs Caisse de dépôt et placement du Québec, Boston-based HarbourVest, Singapore sovereign-wealth fund Temasek and Chinese tech giant Tencent. They join returning LPs Teralys Capital, BDC Capital and Investissement Québec.
4 min read · 30 November 2017
1 min read · 28 November 2017
This year has been eventful for Lumira Capital. The Toronto life-sciences investor held a first close for Fund IV, completed the fund’s debut deals, tied up investing by prior funds, and took a portfolio star public. One milestone was met in this week's announcement of the Series A financing of Kalgene Pharmaceuticals, a developer of treatments for Alzheimer’s disease. Lumira led the undisclosed round and was joined by Anges Québec, Anges Québec Capital, Accel-Rx and family offices. Kalgene is the final deal of Merck Lumira Biosciences Fund, an early-stage vehicle managed by Lumira, which together with the later-stage Lumira Capital II raised $167 million over 2012-2013. With both funds now fully invested, Lumira is positioned to bring Lumira Capital IV to a final close in 2018 and back a new series of North American biotech financings.
4 min read · 27 November 2017
4 min read · 27 November 2017
1 min read · 22 November 2017
4 min read · 21 November 2017
4 min read · 17 November 2017
4 min read · 16 November 2017
1 min read · 15 November 2017
